Terapias anti-inflamatórias emergentes para aterosclerose

##plugins.themes.bootstrap3.article.main##

Daniel Pereira Pena
Maria Luiza Cota Pereira
Luísa Tristão Sanches
Jhonatan Talhamento Mariano
Nicole Sfredo
Victoria Cristina Farani Vieira
Carla Manuella Campelo Guerra Queiroz Campos
Luísa Della Líbera Murari
Jaqueline Priscila Davino
Amanda Carolina Zicatti da Silveira

Resumo

Objetivo: Avaliar a eficácia das terapias anti-inflamatórias emergentes, como os inibidores de interleucina, na redução da progressão da aterosclerose e na prevenção de eventos cardiovasculares em pacientes com aterosclerose. Métodos: Revisão integrativa através da plataforma de base de dados Pubmed. A pesquisa foi feita através da estratégia de pesquisa: (("Anti-Inflammatory Agents"[MeSH]) OR ("Interleukin Inhibitors"[MeSH])) AND (Atherosclerosis). Foram encontrados um total de 664 artigos na base de dados após a aplicação das estratégias de pesquisa. Após a aplicação dos critérios de inclusão e exclusão, foram selecionados 60 artigos, sendo removidos 41 artigos após a análise inicial. Isso totalizou 19 artigos para análise completa. Resultados: Evidencia-se que as terapias anti-inflamatórias possuem potencial para melhorar o prognóstico de pacientes portadores de aterosclerose, porém ainda existem questões como efeitos colaterais, custo das medicações e eficácia no longo prazo. Considerações Finais:  Progressos notáveis na compreensão dos mecanismos subjacentes à inflamação na aterosclerose e no desenvolvimento de estratégias terapêuticas direcionadas aos mesmos apresentam potencial considerável na redução da progressão da aterosclerose e na prevenção de eventos cardiovasculares em pacientes com aterosclerose.

##plugins.themes.bootstrap3.article.details##

Como Citar
PenaD. P., PereiraM. L. C., SanchesL. T., MarianoJ. T., SfredoN., VieiraV. C. F., CamposC. M. C. G. Q., MurariL. D. L., DavinoJ. P., & SilveiraA. C. Z. da. (2023). Terapias anti-inflamatórias emergentes para aterosclerose. Revista Eletrônica Acervo Saúde, 23(12), e14869. https://doi.org/10.25248/reas.e14869.2023
Seção
Revisão Bibliográfica

Referências

1. ALLAM G, et al. The pleiotropic role of interleukin-17 in atherosclerosis. Biomedicine & Pharmacotherapy, 2018; 106: 1412-1418.

2. CHAN YH e RAMJI DP. A perspective on targeting inflammation and cytokine actions in atherosclerosis. Future Med Chem, 2020;12(7):613-626.

3. CHEN S, et al. Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis. J Am Heart Assoc. 2020;9(12):e015513.

4. GAO W, et al. Reductively dissociable biomimetic nanoparticles for control of integrin-coupled inflammatory signaling to retard atherogenesis. Chem Commun (Camb). 2019 Sep 24;55(77):11535-11538.

5. GASPAROTTO FM, et al. Antiatherosclerotic Properties of Echinodorus grandiflorus (Cham. & Schltdl.) Micheli: From Antioxidant and Lipid-Lowering Effects to an Anti-Inflammatory Role. J Med Food, 2019;22(9):919-927.

6. GEORGAKIS MK, et al. Targeting the CCL2-CCR2 axis for atheroprotection. Eur Heart J, 2022;43(19):1799-1808.

7. GLUBA-BRZÓZKA A, et al. Emerging anti-atherosclerotic therapies. International Journal of Molecular Sciences. 2021; 22(22), 12109.

8. GONG C, et al. Parecoxib improves atherosclerotic plaque stability by suppressing inflammation and inhibiting matrix metalloproteinases production. Biomedicine & Pharmacotherapy, 2021; 138: 111423.

9. HERVÁS SM e NAVARRO HG. Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms. Revista Española de Cardiologia, 2019; 72: 767-773.

10. JEON S, et al. Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis. Circulation, 2020; 142(18):1736-1751.

11. KHAMBHATI J, et al. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis. 2018 Sep;276:1-9.

12. KOTTOOR SJ e ARORA RR. The utility of anti-inflammatory agents in cardiovascular disease: a novel perspective on the treatment of atherosclerosis. Journal of cardiovascular pharmacology and therapeutics, 2018; 23(6), 483-493.

13. KOUSHKI K, et al. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clin Rev Allergy Immunol, 2021;60(2):175-199.

14. LIBBY P e EVERETT BM. Novel Antiatherosclerotic Therapies. Arterioscler Thromb Vasc Biol. 2019;39(4):538-545.

15. LIU W, et al. Interleukin-23: A New Atherosclerosis Target. Journal of interferon & cytokine research, 2018; 38(10), 440-444.

16. LUO P, et al. Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6/IL-6R/STAT3 signaling. European Journal of Pharmacology, 2021; 893:173822.

17. MCCURDY S, et al. Potential role of IL-37 in atherosclerosis. Cytokine, 2019;122:154169.

18. MENG Q, et al. Morin hydrate inhibits atherosclerosis and LPS-induced endothelial cells inflammatory responses by modulating the NFκB signaling-mediated autophagy. International Immunopharmacol, 2021; 100:108096.

19. POZNYAK AV, et al. Anti-inflammatory therapy for atherosclerosis: focusing on cytokines. International journal of molecular sciences, 2021; 22(13), 7061.

20. RIDKER PM. From Rescue to Zeus: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Published on behalf of the European Society of Cardiology, 2021; 117, e138–e140.

21. SOEHNLEIN O e LIBBY P. Targeting inflammation in atherosclerosis—from experimental insights to the clinic. Nature reviews Drug discovery, 2021; 20(8), 589-610.

22. STERPETTI AV. Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. Curr Atheroscler Rep, 2020; 22:75: 1-12

23. WACINSKI P, et al. Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS). International Journal of Molecular Sciences, 2021; 22(14), 7486.

24. WANG Y, et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS nano, 2018; 12.9 : 8943-8960.

25. YU J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732.